A lesion may temporarily increase in size when immune cells enter the tumor and produce treatment-related structural changes. This pattern, called pseudoprogression, differs from enlargement caused by continued malignant growth. Interpreting the finding alongside later imaging, clinical findings, and biomarkers helps prevent an early apparent increase from being mistaken for treatment failure.
Tumor size indicates changes in overall burden, while structural features can reveal alterations that are not captured by measurements alone. Biological activity, assessed through blood or tissue biomarkers, adds information about treatment response and immune effects. Considering these dimensions together can clarify whether a tumor is responding, remaining controlled, or showing evidence of resistance.
Serial changes can separate a favorable treatment response from persistent or recurring disease, supporting recognition of therapeutic resistance. Clinical findings and biomarker results also provide context for changes that may reflect treatment-related toxicity rather than tumor behavior. This combined interpretation is particularly important for evaluating immune-based therapies, whose effects may not be reflected by size alone.
Assessment typically combines serial imaging with clinical findings and measurements from blood or tissue. Imaging follows changes in tumor size and structure, whereas clinical observations provide patient-level context. Blood and tissue biomarkers can indicate biological activity or immune-related changes. Using these sources together creates a more informative longitudinal record than relying on one measurement.
Researchers and clinicians compare findings across repeated assessments to determine whether tumor burden is decreasing, changing atypically, remaining controlled, or suggesting resistance. The interpretation can inform decisions about continuing or reconsidering therapy, while clinical findings and toxicity signals add safety context. In immunotherapy studies, this approach helps distinguish delayed response patterns from unfavorable progression.
It provides a framework for evaluating whether immune-based therapies produce meaningful and durable tumor control. Tracking imaging findings alongside blood or tissue biomarkers can support investigation of immune-cell infiltration and other response-associated signals. These measurements also help researchers identify biomarkers that may predict treatment benefit, clarify resistance, and improve interpretation of therapeutic outcomes.